# Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

> **NCT00630409** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Doxil

## Key facts

- **NCT ID:** NCT00630409
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630409, "Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00630409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*